145 related articles for article (PubMed ID: 24902483)
1. Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.
Falgreen S; Laursen MB; Bødker JS; Kjeldsen MK; Schmitz A; Nyegaard M; Johnsen HE; Dybkær K; Bøgsted M
BMC Bioinformatics; 2014 Jun; 15():168. PubMed ID: 24902483
[TBL] [Abstract][Full Text] [Related]
2. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
Gardner SN
Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
[TBL] [Abstract][Full Text] [Related]
3. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
Levasseur LM; Slocum HK; Rustum YM; Greco WR
Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733
[TBL] [Abstract][Full Text] [Related]
4. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
6. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
7. Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions.
Lutz MW; Kenakin TP; Corsi M; Menius JA; Krishnamoorthy C; Rimele T; Morgan PH
J Pharmacol Toxicol Methods; 1995 Sep; 34(1):37-46. PubMed ID: 7496045
[TBL] [Abstract][Full Text] [Related]
8. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.
El-Kareh AW; Secomb TW
Neoplasia; 2005 Jul; 7(7):705-13. PubMed ID: 16026650
[TBL] [Abstract][Full Text] [Related]
9. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
10. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results.
Ribba B; Marron K; Agur Z; Alarcón T; Maini PK
Bull Math Biol; 2005 Jan; 67(1):79-99. PubMed ID: 15691540
[TBL] [Abstract][Full Text] [Related]
11. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
12. On the translation of uncertainty from toxicokinetic to toxicodynamic models--the TCDD example.
Heinzl H; Mittlböck M; Edler L
Chemosphere; 2007 Apr; 67(9):S365-74. PubMed ID: 17224175
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a PPARdelta antagonist.
Elikkottil J; Kohli DR; Gupta K
Cancer Biol Ther; 2009 Jul; 8(13):1262-4. PubMed ID: 19502779
[No Abstract] [Full Text] [Related]
15. On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model.
Unkel S; Belka C; Lauber K
Radiat Oncol; 2016 Jan; 11():11. PubMed ID: 26822015
[TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves.
Hamed SS; Roth CM
J Pharmacokinet Pharmacodyn; 2011 Jun; 38(3):385-403. PubMed ID: 21523388
[TBL] [Abstract][Full Text] [Related]
17. Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures.
Ward JP; King JR
Math Biosci; 2003 Feb; 181(2):177-207. PubMed ID: 12445761
[TBL] [Abstract][Full Text] [Related]
18. Statistical evaluation of mathematical models for microbial growth.
López S; Prieto M; Dijkstra J; Dhanoa MS; France J
Int J Food Microbiol; 2004 Nov; 96(3):289-300. PubMed ID: 15454319
[TBL] [Abstract][Full Text] [Related]
19. Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines.
Abbas-Aghababazadeh F; Lu P; Fridley BL
Sci Rep; 2019 Oct; 9(1):14421. PubMed ID: 31594982
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
